Xoma received preliminary approval to initiate a Phase 2 clinical study of its Xoma 358 drug to treat children over age 2 with hyperinsulinism in the UK.
- GlobeNewswire•2 days agoXOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism
BERKELEY, Calif., Oct. 19, 2016-- XOMA Corporation, a leader in the discovery and development of therapeutic antibodies, announced today the United Kingdom’ s Medicines and Healthcare Products Regulatory ...
- Capital Cube•3 days ago
Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to XOMA Corp. Here are 5 ETF’s with the largest exposure to XOMA-US. Comparing the performance and risk of XOMA Corp. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
XOMA Corporation (XOMA)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||5.01 x 200|
|Ask||5.99 x 100|
|Day's Range||5.26 - 5.67|
|52wk Range||0.34 - 7.33|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||496.36|
|Avg Vol (3m)||830,161|
|Dividend & Yield||N/A (N/A)|